Accounts Receivable, after Allowance for Credit Loss, Current of Syndax Pharmaceuticals Inc from 31 Dec 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Syndax Pharmaceuticals Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
  • Syndax Pharmaceuticals Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $37,996,000, a 400% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Syndax Pharmaceuticals Inc Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $37,996,000 +$30,394,000 +400% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $7,602,000 +$7,602,000 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $0 31 Dec 2023 10-K 03 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.